Mochi vs Mochi: GLP-1 Telemedicine Comparison

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Mochi is a telemedicine platform that connects patients with healthcare providers to prescribe GLP-1 receptor agonist medications for weight management. The platform focuses on accessibility and convenience, delivering prescriptions directly to patients' homes. As of 2024, multiple digital health companies now offer similar GLP-1 prescription services, making it important to understand how platforms like Mochi differentiate and what options exist within the broader weight-management landscape.

Choosing a telemedicine provider for GLP-1 therapy involves evaluating medication formulations, pricing transparency, provider qualifications, and whether the platform supports personalized assessment. Mochi operates within this competitive space, but patients benefit from understanding compounded medication alternatives and how genetic predisposition testing can inform more tailored clinical conversations with their prescribing provider.

What Mochi Offers in the GLP-1 Telemedicine Market

Mochi provides access to GLP-1 medications through a streamlined online consultation model. Patients complete a health assessment, consult with a provider via telehealth, and receive a prescription shipped to their address. The platform emphasizes rapid enrollment and flexible pricing options, positioning itself as a patient-friendly alternative to in-office weight-management clinics.

Mochi typically offers branded GLP-1 medications or compounded formulations depending on inventory and clinical judgment. The platform's pricing and medication selection may vary based on insurance coverage, medication availability, and individual patient eligibility. Understanding what Mochi provides is the first step—but comparing it to other platforms and compounded-medication sources requires broader context about formulation types and clinical support.

Telemedicine Platform Comparison Framework

Multiple telemedicine platforms now compete in the GLP-1 space, each with distinct models for provider engagement, medication sourcing, and patient support. The table below outlines key differentiators to consider when evaluating Mochi against alternatives, including compounded-focused providers like PlexusDx.

Evaluation Factor	Mochi Model	Other Digital Platforms	Compounded-Focused Providers
Provider Qualification	Licensed physicians and nurse practitioners	Varies; many use physician networks	Licensed providers with compounding pharmacy partnerships
Medication Source	Branded or compounded (availability varies)	Branded primary; some offer compounded	Licensed 503A compounding pharmacies exclusively
Genetic or Biomarker Testing	Standard health assessment	Health history-based; limited biomarker testing	Optional Precision Peptide Genetic Test to support GLP-1 pathway analysis
Price Transparency	Publicly listed; may vary by medication	Variable; subscription or per-dose models	Clear monthly pricing for compounded formulations
Ongoing Clinical Support	Follow-up consultations as needed	Varies by platform subscription tier	Dose titration guidance; genetic predisposition context available

Compounded vs. Branded GLP-1 Medications: Clinical Context

Branded GLP-1 medications (such as Ozempic, Wegovy, Zepbound, and Mounjaro) are FDA-approved, mass-manufactured products with extensive clinical trial data supporting their efficacy and safety profiles. Compounded GLP-1 medications are prepared by licensed 503A pharmacies according to prescriber specifications and must meet pharmacy-grade quality standards but are not FDA-approved drugs.

Mochi may offer either formulation depending on availability and patient preference. Compounded alternatives provide flexibility in dosing, delivery method, and cost, though they require equally rigorous provider oversight. Neither formulation type guarantees superior outcomes for all patients—individual response varies based on genetics, metabolism, lifestyle, and adherence. Patients should discuss formulation choice directly with their prescribing provider based on clinical need and access.

Genetic Predisposition and Personalized GLP-1 Selection

Emerging research suggests that genetic variation in GLP-1 receptor pathways (GLP1R gene), incretin glucose-dependent insulinotropic peptide receptor (GIPR), and appetite-regulation genes (FTO, MC4R) may influence how individual patients respond to GLP-1 therapy. These genetic predispositions do not determine medication response but may provide context for clinical conversations about which formulation or titration approach aligns with a patient's biochemical profile.

Standard telemedicine platforms like Mochi typically use health history and lifestyle assessment to guide prescribing. Compounded-medication providers may offer optional genetic testing—such as PlexusDx's Precision Peptide Genetic Test—to provide additional biological context. This test examines common variants in peptide metabolism pathways and should be interpreted with a qualified healthcare provider as one input among many clinical factors, not as a predictor of guaranteed outcomes.

Safety, Eligibility, and Provider Oversight

All legitimate GLP-1 providers—including Mochi and compounded-medication sources—must verify patient eligibility through medical screening. Contraindications include personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pregnancy, and severe gastrointestinal disease. Patients with these conditions should not use GLP-1 medications regardless of platform or formulation type.

Regular provider follow-up is essential for any GLP-1 therapy to monitor for side effects, assess weight-loss progress, and adjust dosing. Mochi provides telehealth consultations for this purpose. Compounded-medication providers like PlexusDx partner with licensed prescribers to ensure ongoing clinical oversight. Both pathways require honest communication about health status, medication adherence, and any adverse effects. Patients should never use GLP-1 medications without active provider guidance.

How PlexusDx Supports a More Personalized Approach

PlexusDx specializes in compounded GLP-1 medications from licensed 503A pharmacies, offering semaglutide, tirzepatide, and microdose protocols at transparent pricing. Unlike platform-based services, PlexusDx emphasizes precision assessment and provider collaboration—integrating optional genetic testing to support more informed treatment conversations rather than replacing clinical judgment.

The Precision Peptide Genetic Test available through PlexusDx examines variants in GLP1R, GIPR, FTO, and MC4R genes—markers that may provide biological context for how an individual's metabolism and appetite regulation systems function. This test is intended to complement, not replace, standard medical evaluation. Results should be interpreted with a qualified healthcare provider as one factor among overall health history, current medications, lifestyle, and clinical goals.

Patients evaluating GLP-1 options—whether through Mochi, other telemedicine platforms, or compounded-medication providers—benefit from asking their healthcare provider: What is my eligibility? How will my response be monitored? Are there genetic or biomarker insights available to personalize my approach? PlexusDx supports these conversations by offering direct access to compounded medications and optional genetic assessment, empowering patients and providers to make evidence-informed decisions.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What exactly is Mochi and how does it differ from other telemedicine GLP-1 platforms?

Mochi is a direct-to-consumer telemedicine platform that connects patients with licensed providers for GLP-1 prescriptions. It differs from platforms like Ro, Calibrate, and others primarily in provider network, medication availability, and pricing structure. Mochi emphasizes convenience and accessibility, but all reputable platforms require med...

Does Mochi offer compounded GLP-1 medications or only branded versions?

Mochi's medication inventory varies by region and availability. The platform may offer both branded medications and compounded formulations depending on stock and clinical judgment. Patients should ask Mochi directly about formulation options available in their location and discuss which approach aligns with their preferences and insurance cover...

How does PlexusDx's compounded GLP-1 option compare to medications through Mochi?

PlexusDx partners with licensed 503A compounding pharmacies to offer semaglutide and tirzepatide injections starting at $149 monthly, plus optional genetic testing. Unlike platform-based services, PlexusDx emphasizes direct provider partnership and transparent pricing. Both pathways require medical eligibility; the choice depends on formula...

Are compounded GLP-1 medications from PlexusDx as safe as FDA-approved branded drugs?

Compounded GLP-1 medications prepared by licensed 503A pharmacies meet pharmacy-grade quality and safety standards but are not FDA-approved drugs. Both compounded and branded formulations require medical oversight and regular provider follow-up. Safety depends on proper screening, dosing, monitoring, and patient adherence—not formulation source ...

Can genetic testing help me decide between Mochi and other GLP-1 providers or formulations?

PlexusDx offers the Precision Peptide Genetic Test ($99 add-on or $298 standalone) to examine variants in GLP-1 pathway genes. This test may provide biological context to support a conversation with your provider about personalized dosing or formulation. Genetic predisposition does not determine outcomes; it should complement, not replace, medic...

Mochi vs Mochi: Evaluating Telemedicine GLP-1 Platforms for Personalized Weight Management